IMVT vs. MRNA, VTRS, RDY, ASND, SRPT, PCVX, QGEN, ROIV, RVMD, and LNTH
Should you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Moderna (MRNA), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.
Immunovant vs.
Immunovant (NASDAQ:IMVT) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, community ranking, profitability, dividends and earnings.
Moderna received 83 more outperform votes than Immunovant when rated by MarketBeat users. However, 78.11% of users gave Immunovant an outperform vote while only 53.88% of users gave Moderna an outperform vote.
Immunovant presently has a consensus price target of $41.00, suggesting a potential upside of 118.20%. Moderna has a consensus price target of $59.00, suggesting a potential upside of 83.69%. Given Immunovant's stronger consensus rating and higher possible upside, research analysts clearly believe Immunovant is more favorable than Moderna.
Immunovant has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500.
Immunovant has higher earnings, but lower revenue than Moderna. Immunovant is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.
Immunovant has a net margin of 0.00% compared to Moderna's net margin of -110.04%. Moderna's return on equity of -28.74% beat Immunovant's return on equity.
In the previous week, Moderna had 13 more articles in the media than Immunovant. MarketBeat recorded 25 mentions for Moderna and 12 mentions for Immunovant. Moderna's average media sentiment score of 0.42 beat Immunovant's score of 0.39 indicating that Moderna is being referred to more favorably in the news media.
47.1% of Immunovant shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 5.9% of Immunovant shares are owned by insiders. Comparatively, 11.0% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Moderna beats Immunovant on 10 of the 17 factors compared between the two stocks.
Get Immunovant News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunovant Competitors List
Related Companies and Tools
This page (NASDAQ:IMVT) was last updated on 3/28/2025 by MarketBeat.com Staff
